Bayer may build new plant, partner innovative biotech start-ups in S'pore

German pharma giant sees potential in mRNA-based vaccines, therapies

New: Gift this subscriber-only story to your friends and family

Bayer may build a new production facility in Singapore to support the ground-breaking cell and gene therapies it is developing to cure Parkinson's disease.

The German multinational, one of the world's top pharmaceutical companies, told The Straits Times it is also looking to partner innovative biotechnology start-ups, including those working on mRNA-based vaccines and therapies.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.

A version of this article appeared in the print edition of The Straits Times on December 07, 2021, with the headline Bayer may build new plant, partner innovative biotech start-ups in S'pore. Subscribe